Morgan Stanley on Sarepta (SRPT): 'Elevidys Approval in Japan Further Confirms Favorable Benefit/Risk Profile'
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating and $113.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
